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Abstract
CADASIL and CARASIL are hereditary small vessel diseases leading to vascular dementia.
CADASIL commonly begins with migraine followed by minor strokes in mid-adulthood.
Dominantly inherited CADASIL is caused by mutations (n > 230) in NOTCH3 gene, which
encodes Notch3 receptor expressed in vascular smooth muscle cells (VSMC). Notch3
extracellular domain (N3ECD) accumulates in arterial walls followed by VSMC degenera-
tion and subsequent fibrosis and stenosis of arterioles, predominantly in cerebral white
matter, where characteristic ischemic MRI changes and lacunar infarcts emerge. The likely
pathogenesis of CADASIL is toxic gain of function related to mutation-induced unpaired
cysteine in N3ECD. Definite diagnosis is made by molecular genetics but is also possible by
electron microscopic demonstration of pathognomonic granular osmiophilic material at
VSMCs or by positive immunohistochemistry for N3ECD in dermal arteries.
In rare, recessively inherited CARASIL the clinical picture and white matter changes are
similar as in CADASIL, but cognitive decline begins earlier. In addition, gait disturbance,
low back pain and alopecia are characteristic features. CARASIL is caused by mutations
(presently n = 10) in high-temperature requirement. A serine peptidase 1 (HTRA1) gene,
which result in reduced function of HTRA1 as repressor of transforming growth factor-β
(TGF β) -signaling. Cerebral arteries show loss of VSMCs and marked hyalinosis, but not
stenosis.
INTRODUCTION
The acronyms CADASIL and CARASIL—two hereditary small
vessel diseases (SVD)—differ from each other only by D vs. R
(cerebral autosomal dominant vs. recessive arteriopathy with
subcortical infarcts and leukoencephalopathy), which may confuse
at least those who less actively follow the SVD literature. The
acronyms imply a difference only in the mode of inheritance—
dominant vs. recessive—however, their gene defects, clinical pic-
tures, imaging findings and pathologies do differ from each other
to such an extent that alert clinicians, radiologists and pathologists
should be able to distinguish these two SVD entities, the definite
diagnoses of which would then emerge at the latest in molecular
genetic analyses. In this article, we describe first for CADASIL
and thereafter for CARASIL the basic clinical findings, genetics,
biochemistry, pathologies and suggested pathogeneses of these
two entities with some similarities but at the same time major
differences. Finally, the present situation of and prospects for
evidence-based therapeutics is discussed.
HISTORY
The first CADASIL family—later verified by genetic analysis of
old tissue specimens—was reported by van Bogaert as “hereditary
Binswanger’s disease” in 1955 (128). Thereafter, the disease enti-
ties resembling the present CADASIL received many different
names (e.g. chronic familial vascular encephalopathy, Familiare
zerebrale Arteriosklerose, Familiäre zerebrale Gefässerkrankung,
familial disorder with subcortical ischemic strokes, dementia and
leukoencephalopathy and familial Binswanger’s syndrome). With
the knowledge of that time, it is not surprising that CARASIL (also
known as Maeda syndrome) in 1960 was described by Nemoto
similarly as a form of Binswanger syndrome and then published by
Maeda et al in 1976 (81) as multifocal softenings in the cerebral
white matter caused by cerebral angiitis (Binswanger’s disease).
The discovery of the causative gene defects then finally and defi-
nitely specified these two SVDs: For CADASIL, the linkage to
chromosome 19 was identified in 1993 (125) and the causative
NOTCH3 gene on 19p13 was discovered in 1996 (54). For
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CARASIL, the defective HTRA1 gene on chromosome 10q25 was
determined in 2009 (45).
EPIDEMIOLOGY
CADASIL
After the gene defect of CADASIL was established and doctors
became better aware of this entity, the number of both reported and
diagnosed cases increased rapidly. At present, CADASIL is the
most common hereditary vascular dementia and it has been
reported in all ethnic groups from Far West to Far East. However,
exact surveys of its prevalence are few. In west Scotland, the
prevalence of patients with definite diagnosis in 2005 was 1.98/
100 000 and that of predicted mutation carriers was 4.14/100 000
(105). In Northeast England, in an outbred Western European
population, the minimum prevalence for definite cases in 2012 was
1.32/100 000 (95). In geographic locations, where the population
has a more limited genetic background, such as Finland and Gran
Canaria island, ancestor phenomena and/or exceptionally high
prevalences have been recorded. In Finland (population about 5
million), the dominant mutation p.Arg133Cys was introduced in
the late 1600s or early 1700s (93), the prevalence being about
4/100 000. The ancestor effect is still more striking on the island of
Gran Canaria, where the prevalence reaches 14/100 000 (121
patients with p.Arg207Cys mutation in a population of about
900 000; Drs. A Santana and J Delgado, pers. comm.). In Canada
and United States, the prevalence numbers have been surprisingly
low (in most Canadian provinces < 1/100 000, Dr. V Saly, pers.
comm.) considering the high standard of neurology in those coun-
tries. Another approach by analyzing the number of CADASIL
cases among patients with lacunar infarcts and leukoaraiosis gave
frequencies of 11% (one out of nine) for patients under 50 years
and 2% (one out of 48) for patients under 65 years of age (32). In
a Korean study of 151 consecutive acute ischemic strokes (mean
age 70 years), 4.0% (n = 6) were diagnosed to suffer from
CADASIL (21). The percentages might be somewhat higher, as
these two last mentioned studies used only a limited screening test
for NOTCH3 mutations.
CARASIL
CARASIL is a very rare disease. Until recently, only somewhat
over 50 cases have been reported (39, 97), 48 from Japan, three
from China (19, 131) and one case each from Spain (83), Romania
(9) andTurkey (8).With the growing awareness also outside the far




CADASIL is—as its name implies—autosomally dominantly
inherited, and only a few patients with definite de novo mutations
have been reported (55). The defective gene is NOTCH3 in
19p13.1–13.2. The 33 exons of NOTCH3 encode a single pass
transmembrane heterodimer receptor protein Notch3 (N3) com-
prising 2321 amino acids. Similarly, as all Notch receptors, Notch3
is synthesized as a full-length protein (Figure 1), which is subse-
quently proteolytically cleaved (S1 cleavage) by furin into two
parts. The N-terminal extracellular domain (N3ECD, 210 kDa) is
composed of 34 epidermal growth factor-like repeats (EGFr), each
of which encompasses six cysteine residues, followed by three
Figure 1. A schematic presentation of Notch signaling. Notch3 is con-
stitutively cleaved by furin (S1) and the bipartite molecule is inserted to
the plasma membrane (PM). The extracellular domain (N3ECD) consists
of 34 epidermal growth factor (EGF)-like repeats, followed by three
notch/lin-12 repeats, a transmembrane domain and an intracellular
domain (NICD), which contains seven ankyrin repeats. The binding site
of the ligand (in human Delta or Jagged) is at EGF repeats 10–11.
Upon binding, N3ECD is cleaved external to the intramembranous
domain (S2). Thereafter occurs the intramembranous S3 cleavage and
NICD enters the nucleus to release the repressor molecules CoR and
HDAc, and it binds to a transcription regulator of CSL family, RBP-Jκ,
and activates transcription. CADASIL mutations are in EGF repeats 1–32
(exons 2–23) between the asterisks. EC = extracellular space, IC =
intracellular space, NM = nuclear membrane, N = nucleus, TACE =
tumor necrosis factor α-converting enzyme, HD = heterodimerization
domain, CoR and HDAc = repressors, HAc and MAML1 = components
of an activation complex.
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Notch/Lin12 repeats. At the heterodimerization domains (HD-N
and HD-C), N3ECD is non-covalently connected to the 97 kDa
C-terminal part, which comprises a transmembrane (N3TMD) and
an intracellular domain (N3ICD; together N3TMIC). N3ICD con-
tains seven ankyrin repeats (Figure 1).
Notch3 belongs to the Notch family (four members in
mammals), whose signaling pathways are indispensable during
development of most organs. Their importance is reflected by the
presence of orthologous genes with high degree of homology from
nematodes to man. Notch repertoire during organogenesis, includ-
ing vasculogenesis, covers for example stem cell renewal, cell
proliferation, determination of cell fate and differentiation and
apoptosis. The exact function of Notch3 is not known in adult
humans, in whom Notch3 is expressed predominantly in VSMCs
(56, 103), the molecular phenotype and metabolic characteristics
of which cells appear to be different in different vascular beds (for
details see succeeding sections).
The Delta/Serrate/Lag-2 (DSL) ligands of Notch receptors
belong to the Delta-like family (DLL1, 3 and 4) and Serrate
family Jagged (Jag 1 and 2). They have similar molecular struc-
ture as Notch receptors, that is they are transmembrane proteins,
the extracellular domain of which contains several EGFrs.
Although both the ligands and Notch receptors are presented on
the surface of vascular smooth muscle cells (VSMC), the ligands
transactivate Notch receptor on the neighboring cells, whereas
Notch receptors expressed on the same cell are cis-inhibited (35).
The ligand-binding site in Notch3 is at EGFr 10–11. Upon
binding of its ligand, N3ECD is non-enzymatically dissociated
from the heterodimeric Notch3 and the bound ligand and N3ECD
are transendocytosed into the ligand-expressing cell. Thereby the
membrane-bound C-terminal part of Notch3 (composed of
N3TMD and N3ICD) becomes exposed for cleavage by
ADAM10 or by ADAM17 (also known as TNF-alpha converting
enzyme; TACE) just outside the plasma membrane (S2 cleavage),
whereafter the final S3 cleavage by γ-secretase (the same enzyme
as in Alzheimer’s disease) can occur within the membrane to
detach N3ICD from N3TMD (11, 96). The transendocytosed non-
mutated N3ECD is degraded in the ligand-presenting cell.
N3ICD enters the nucleus of the receptor-presenting cell and
interacts with RBP-Jκ and co-activators to activate transcription
of its target genes (37, 38) (Figure 1).
The pathogenic mutations—so far over 230 different reported—
are located in exons 2–24 in the N3ECD, with prominent cluster-
ing in exons 3 and 4 encoding EGFr 2–5 (over 40% of mutations
in over 70% of families occur in these exons). A great majority of
mutations (>95%) are missense mutations, which cause either
substitution of a wild type (wt) cysteine with another amino acid or
vice versa. In addition, eight different deletions, two duplications
(70, 82) and two splice site mutations (57, 112) have been
reported. Remarkably, all these mutations result in an uneven
number of cysteine residues in the affected EGFr, which situation
appears to be crucial in the pathogenesis of CADASIL. However,
at least 11 patients/families, whose clinical picture was considered
compatible with CADASIL and who carried a non-cysteine muta-
tion in NOTCH3, have been reported. Besides, we have been
consulted about several such patients. Whether the CADASIL-like
disease in these patients has a causal relationship with the non-
cysteine NOTCH3 mutation has been debated and remains to be
investigated (23, 24, 88) (see also Pathogenesis section).
At present, five patients with homozygous cysteine mutations
in NOTCH3 [Tuominen et al: p.Arg133Cys (126), Liem et al:
p.Arg578Cys (78), Ragno et al: p.Gly528Cys (104), Soong et al:
p.Arg544Cys (118) and Vinciguerra et al: p.Cys183Ser (130)]
have been reported.
CARASIL
Analogously, CARASIL is—as its name implies—autosomally
recessively inherited and, thus, mutations on both alleles, either
homozygous or compound heterozygous, are required to cause the
disease.
The gene defect of CARASIL was discovered collaboratively by
a large Japanese group of researchers directed by Professors O.
Onodera and S. Tsuji, the majority of the participants being based
at Niigata University (45). Five families with clinical CARASIL
were enrolled and they were first analyzed by genome-wide
linkage and thereafter the defective gene was fine mapped to a
2.4-Mb region on chromosome 10q. High-temperature require-
ment A serine peptidase 1 (HTRA1) was selected as a candidate
gene because it is expressed in the blood vessels, skin and bone.
HTRA1 in human is composed of nine exons encoding a protein
consisting of 480 residues and comprising four functional domains
(Figure 2). The exons 3–6 encode the main domain of a trypsin-
like serine protease that represses signaling by transforming
growth factor-β (TGF-β) family members (45).
The sequence analysis by Hara et al (45) revealed in the serine
protease domain of HTRA1 four homozygous mutations: two
missense and two nonsense mutations (Table 1 and Figure 2),
which were not discovered in 125 controls. Thereafter (at least),
four novel missense mutations have been reported and among
them the first Caucasian patient (83) (Table 1). Another Caucasian
patient fromTurkey (8) carried the same nonsense mutation as one
of the original families of Hara et al (45). The first and only
reported compound heterozygous patient was also Caucasian (9)
(Table 1); this individual carried a classic missense mutation in
exon 4 of HTRA1 paired with an exceptional single nucleotide
deletion in exon 1 that causes a frameshift.
Figure 2. A schematic presentation of HTRA1 mutations. The muta-
tions reported in Far-Eastern patients are presented below the gene and
those in Caucasian patients are presented above the gene. Missense
mutations are presented in black, nonsense mutations in red and the
compound heterozygous mutation in green. [Domains of HTRA1. Red:
Insulin-like growth factor binding protein domain. Green: Kazai-type
serine protease inhibitor domain. Blue: Trypsin-like serine protease
domain. Yellow: PDZ domain. Scheme modified after Hara et al (45); for
details see Table 1].
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HTRA1 belongs to the family of high-temperature requirement
A serine proteases, which in mammals participates in a variety
of physiological processes, such as cell signaling and protein
degradation, and is associated with development of the muscu-
loskeletal system. For CARASIL, important repression of TGF-β
signaling occurs as follows (97, 116, 124): TGF-β1 is synthesized
as a pre-pro-protein. In the endoplasmic reticulum, proTGF-β1 is
dimerized and in trans-Golgi network (TGN), proTGF-β1 is then
cleaved by furin convertase. The two cleaved products of proTGF-
β1, latency-associated peptide (LAP) and the mature TGF-β1
peptide, are connected non-covalently to yield a small latent
TGF-β1 complex. This small latent TGF-β1 complex is bound to
LTBP1 by LAP forming the large latent TGF-β1 complex, which
complex is secreted and sequestered in the extracellular matrix
(ECM). Different proteases/integrins in the ECM can cleave LAP
to release the mature TGF-β, which then can bind to its receptors.
HTRA1 represses TGF-β signaling by cleaving proTGF-β1 in the
endoplasmic reticulum (ER) and the cleaved products are
degraded by ER-associated protein degradation (ERAD), resulting
in the reduction of mature TGF-β1.
Hara et al (45) demonstrated that both missense mutations and
one nonsense mutation (p.Arg302X) resulted in protein products
with clearly lowered protease activity by 21%–50%, which was not
enough to repress signaling by the TGF-β family, whereas the
other nonsense mutation (p.Arg370X) caused loss of HTRA1 pro-
tease activity by nonsense mediated decay of mRNA. Upregulated
TGF-β signaling is known to result in increased synthesis of ECM
proteins with consequent vascular fibrosis (71). Both immunohis-
tochemical analysis and in situ hybridization of the cerebral small
arteries in CARASIL patients showed increased expression of
fibronectin and versican in the thickened tunica intima and of
TGF-β1 in the tunica media.
CLINICAL PICTURES
Even though the gene defects are known, the exact pathogenesis,
that is the mechanisms by which the defective pathogenic genes
cause these two SVDs are still to be discovered. In spite of that, we
have now an effective arsenal of both knowledge and machinery to
diagnose these patients.
Clinical picture of CADASIL
As the clinical picture of CADASIL has been described in detail in
several excellent reviews (2, 18, 28, 61, 62, 101), only a short
summary of the clinical findings—relevant to the theme of this
mini-symposium—is described.The wide variability of the clinical
picture, also between family members with the same mutation and
even between monozygotic twins (94), is repeatedly emphasized.
There is a relative lack of classic vascular risk factors, but for
example arterial hypertension, hypercholesterolemia, smoking
and diabetes mellitus are known to impact on CADASIL patients
(2, 18, 28, 61, 62, 117). The four cardinal manifestations are:
(i) Migraine with aura: About 20%–40% of CADASIL patients
manifest with this symptom, while up to 60% suffer from
migrainous headache without aura. The average age of onset is
around 30 years of age, although it may appear even before the age
of 10 years, for example (18, 43), and besides, the aura may be
exceptionally severe, for example (2, 18, 28, 43, 61, 129). Remark-
ably, in female patients, late pregnancy or puerperium often
elicits their first attack of migraine with aura or aggravates such
attacks (108).
(ii) Ischemic attacks: Ischemic strokes, often preceded by tran-
sient ischemic attacks (TIA, which are difficult to distinguish from
severe migrainous aura) are the most common (up to 85% of
symptomatic patients) manifestations. The age of first-ever stroke
varies vastly. The youngest reported patient with stroke was only
11 years of age (43), whereas some exceptional patients do not
suffer their first-ever stroke until they have reached their 70th
birthday (133) (Miao et al unpublished). Such late-onset cases
may easily remain undiagnosed being considered “just common
old age strokes”. The mean ages reported are around 40–50 years
(2, 18, 28). The strokes are almost always subcortical and typically
present as lacunar syndromes, such as pure motor or sensory
deficits, dysarthria-clumsy hand syndrome, expressive dysphasia
or visual field defects. Major strokes because of larger infarcts in
the supply territories of major cerebral arteries are rare, most likely
coincidental, not related to CADASIL.
(iii) Cognitive decline and dementia: Impairment in executive
function and working memory was recorded already before TIA
and strokes. By testing for these two functions and for mental
Table 1. CARASIL mutations. Abbreviations: homoz = homozygous; heteroz = heterozygous; ms = missense; ns = nonsense; del = deletion.
E Mutation type Nucleotide Protein Ethnicity Publication
Far-Eastern patients
3 homoz, ms c.754G > A p.Ala252Thr Japanese Hara et al N Engl J Med 2009; 360: 1729–1739. (45)
4 homoz, ms c.889G > A p.Val297Met
4 homoz, ns c.904C > T p.Arg302X
6 homoz, ns c.1108C > T p.Arg370X
4 homoz, ms c.821G > A p.Arg274Gln Japanese Nishimoto et al Neurology 2011; 76:1353–1355.
4 homoz, ms c.854C > T p.Pro285Leu Chinese Chen et al J Int Med Res 2013; 41:1445–1455. (19)
6 homoz, ms c.1091T > C p.Leu364Pro Chinese Wang et al CNS Neurosci Ther 2012; 18: 867–869. (131)
Caucasian patients
4 homoz, ms c.883G > A p.Gly295Arg Spanish Mendioroz et al Neurology; 2010; 75: 2033–2035. (83)
6 homoz, ns c.1108C > T p.Arg370X Turkish Bayrakli et al Turk Neurosurg 2014; 24:67–69. (8)
1
4




Romanian Bianchi et al Neurology 2014; 82:898–900. (9)
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speed, non-demented mutation carriers could be distinguished
from controls. Episodic memory was relatively well preserved
until late stage of the disease (3, 27, 101, 120), but eventually the
patients develop a serious dementia of subcortical vascular type.
(iv) Psychiatric manifestations: 20%–30% of CADASIL
patients suffer from mood disturbances, the most common and
serious being depression, which is expected in patients who have
experienced the disease in their family and have an insight of their
own disease. Apathy is a very common symptom; up to 41% of
patients in a large French CADASIL cohort were apathetic. It
appears to correlate with the patients’ age, severity of cognitive
impairment, other neuropsychiatric symptoms (often depression)
and load of subcortical tissue lesions (106). Manic episodes are
relatively uncommon (ca. 2%), although CADASIL may some-
times be mistaken for bipolar mood disorder before its true nature
is discovered. Additional disturbances have been reported, includ-
ing schizophrenia, psychosis, paranoia, aggression and dysthymia
(14, 18, 28, 129).
Imaging in CADASIL
The imaging findings in SVDs including CADASIL are described
in the article by Salamon in this mini-symposium (113). Here, we
present a few essential magnetic resonance imaging (MRI) find-
ings [with reference to figures in the article (113)] complemented
by selected examinations applying special imaging methods.
White matter hyperintensities (WMHI) in temporopolar region
and capsula externa on T2-weighted (T2w) or Fluid-Attenuated
Inversion Recovery (FLAIR) MRI have been considered pathog-
nomonic findings in CADASIL [figure 3B in (113)]. These are
complemented by periventricular, usually spotty leukoaraiosis,
which gradually involves most of the cerebral WM [figure 4
in (113)]. Interestingly, the prominence of the characteristic
temporopolar WMHI may depend on the patients’ ethnic back-
ground, being lesser in Chinese patients (72, 132). These MRI
lesions are detectable already in the presymptomatic stage even
before the age of 20 years and the youngest reported patient with
subcortical foci of increased T2 hyperintensity was only 8 years
old (48). The characteristic lacunar infarcts can be visualized in
computerized tomography (CT) and in T1w or fluid-attenuation
inversion recovery (FLAIR) MRI as areas of decreased signal,
predominantly in cerebral WM and deep grey matter (GM)
[figure 3A in (113)]. Lacunar infarct lesion load is the most impor-
tant MRI parameter associated with cognitive dysfunction in
CADASIL (77). Occurrence of simultaneous multiple acute
infarcts, such as those usually caused by and ascribed to
embolization, has been detected in CADASIL by diffusion-
weighted MRI (41).
The above-mentioned leukoaraiosis pattern implies a widely
distributed diffuse leukoencephalopathy, which by diffusion tensor
imaging (DTI) is detected as increased water diffusivity and loss of
anisotropy, that is the diffusion ofwater can occurmore freely in any
Figure 3. Loss of hair is clearly noticeable
already at the age of 34 years in this male
CARASIL patient (A). At the age of 33 years,
T2-weighted MRI disclosed diffuse
leukoencephalopathy and lacunes (B and C).
Figure 4. Three old infarcts of moderate size
in cerebral white matter (open arrows) and
smaller lacunar infarcts in putamen bilaterally
(arrows) in a 65-year-old female CADASIL
patient with p.Arg133Cys Notch3 mutation.
Note the relatively spared cortex except for
the ischemic lesion in temporal cortex
(arrowhead) because of atherosclerotic
occlusion of a middle cerebral artery branch
[black triangle; (A)]. In this same patient’s
caudate nucleus, the lesions are more severe
than in putamen. In the WM of the centrum
semiovale, there is another small cystic
infarct [open arrow; (B)]. Lateral ventricles in
both (A) and (B) are widened because of
ischemic tissue loss.
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direction. This indicates accumulation of fluid in enlarged extra-
cellular space (vasogenic/interstitial brain edema) associated with
microstructural pathology, myelin and axonal damage (see Histo-
pathology post-mortem section). Corresponding to such tissue
damage, DTI results correlate better with the patients’ clinical
deterioration thanT2w images (16). DTI alterations are also detect-
able in the normal-appearingWM outside theT2w hyperintensities
as a harbinger of incipient microstructural abnormalities.
In one-third to two-thirds of CADASIL patients, T2*
(gradient echo) MRI discloses small hypointensities, microbleeds
[figure 3A in (113)], which represent perivascular accumulations
of hemosiderin laden macrophages indicating focal extravasation
of red blood cells (Figure 10). Microbleeds are clinically silent and
their frequency was not associated with the severity of patient’s
cognitive dysfunction (73). Microbleeds are primarily located in
the cerebral cortex, subcortical WM, basal ganglia and brainstem
[figure 3a in (113); all outside ischemic lesions and 82% outside
regions that are hyperintense in T2w MRI (29)]. Their frequency
increases with patients’ age, blood pressure, volume ofT2w lesions
and antiaggregant therapy (29, 73). Microbleeds are not specific to
CADASIL, but they also occur in other SVD of the central nervous
system, such as arteriolosclerosis and amyloid angiopathy. They
were considered to be largely an independent manifestation of the
underlying angiopathy (29). Although direct association has not
been reported, concerns that microbleeds may increase the risk of
intracerebral hemorrhage have been expressed (73).
As described in the succeeding sections, the brunt of brain
pathology targets small arteries and arterioles. However, the arter-
ies and arterioles in SVDs are too small to be specifically visual-
ized by conventional MRI. The application of 7 tesla MRI (10) to
in vivo visualization of the pathologies developing in small WM
arteries in CADASIL and other SVDs will certainly provide inter-
esting new data.
Clinical picture in CARASIL
The clinical features of CARASIL have been described in several
articles (39, 40, 97, 136) (and many in Japanese), hence we present
here again only an outline. Neurologic symptoms and signs are in
many respects similar to those in CADASIL with lack of hyper-
tension having been more explicitly emphasized in some reports
on CARASIL (40). Half of the patients experience recurrent
ischemic strokes, most often of the lacunar type. These lead to
stepwise, progressive impairment of brain functions and finally
to dementia, usually by the age of 30 to 40 years. Memory dys-
function in CARASIL appears to be more severe than in
CADASIL. An interesting sign—visible to naked eye—is prema-
ture diffuse baldness, which predominantly concerns male patients
(Figure 3A). Because the connective tissue is also affected in
CARASIL, about 80% of the patients suffer from low back pain
because of disk herniation and spondylosis deformans, usually
between lower thoracic or upper lumbar levels. Cervical
spondylosis is also often found.
Imaging in CARASIL
Brain MRI findings are in many respects similar to those in
CADASIL (39, 97, 136). In T2w, MRI hyperintensities occur in
periventricular and deep WM and sometimes even in anterior
temporal WM and capsula externa, as is typical of CADASIL
(Figure 3B and C). In CARASIL, the WM changes appear to
develop more homogeneously than in CADASIL and the U-fibers
are relatively spared. Multiple lacunar infarct are also detected,
predominantly in the basal ganglia and thalamus. On spinal MRI,
cervical and lumbar spondylosis and disk degeneration become




The reduction of cerebral blood flow (CBF) in CADASIL has
been found by applying several different imaging methods, such as
positron emission tomography (PET) (15, 127), Doppler
sonography (76) and MRI bolus tracking method (12, 17). Corre-
sponding to the imaging findings and the sparing of cerebral cortex
(see Pathology of CADASIL section), CBF is first and predomi-
nantly reduced in cerebral WM. This was detected by PET already
at a presymptomatic stage, although it became more apparent at
ages above 30 years, when also the strokes begin to appear. CBF in
the cerebral cortex was not reduced until later ages and never to
such an extent as in WM. Corresponding to the reduction in CBF,
morphological studies have shown definite stenosis of WM arte-
rioles (for details see Pathology of CADASIL section) (84). In a
presymptomatic patient, the oxygen extraction fraction (OEF) was
shown to increase indicating that the brain thereby attempts to
compensate for the decreased CBF by increasing OEF (15). On the
other hand, the cerebral metabolic rate of oxygen (CMRO2) (15)
and glucose consumption (CMRgluc) (127) were not reduced until
later stages parallel to the development of dementia and tissue loss,
indicating that the early stage decrease in CBF is because of the
arteriopathy instead of being just secondary to tissue loss.
Concordantly, by applying bolus tracking and Doppler
methods, CBF and cerebral blood volume (CBV) were found to
be reduced within T2w hyperintense areas in the WM, more
severely in demented than in non-demented patients (12, 17).
Besides, in the normal-appearing WM, a trend of reduced CBV
was noticed (17). Furthermore, the hemodynamic reserve is
reduced in CADASIL patients because acetazolamide induced a
lesser increase in CBF in CADASIL patients’ T2w hyperintense
WM areas than in control subjects’ WM (17). This is well under-
standable, as CADASIL patients’ WM arteries have become sten-
osed and stiffened by fibrosis (84) (see Pathology of CADASIL
section) and thus less responsive to acetazolamide. This may also
be the cause of the prolonged arteriovenous cerebral transit time
in both disabled and non-disabled CADASIL patients as demon-
strated by Liebetrau et al (76). Experimental studies have given
similar results: transgenic mice expressing p.Arg90Cys-mutant
human NOTCH3 showed reduced responses to hypercapnia and
acetazolamide, higher cerebrovascular resistance during hyper-
tension and their lower limit of CBF autoregulation was shifted to
higher blood pressures (69).
Retinal vasculature offers an exceptional and excellent in vivo
view of arterioles. In CADASIL patients, retinal capillary blood
flow was found to be mildly to moderately reduced (47). Further-
more, general arterial narrowing and arteriovenous nickings
were common. Straightening of the retinal arterioles and a
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marked wall reflex occurred and the arterio-venous (A/V) ratio
was significantly lower than that in the controls. However,
although CADASIL does induce a wide variety of
ophthalmologic alterations, these resulted in only minimal func-
tional disturbances and most often in no major ischemic injuries
in the retina. Thus, the retina is relatively spared, which conclu-
sion conforms with the results in the cerebral cortex, with which
the retina and its arterioles are analogous (109).
As the arteriopathy in CADASIL is generalized, it is not sur-
prising that vasoregulation is disturbed also in the systemic
vasculature. Stenborg et al (119) showed in the forearm of
CADASIL patients that endothelium-dependent vasodilation is
impaired in resistance arteries, but not in a large conduit artery, a.
brachialis. This impairment results in reductions in both basal and
stimulated blood flow. Similarly, Gobron et al (42) reported that
after the release of forearm cuff occlusion and after nitroglycerin
administration, the maximum changes in the diameter of the
brachial artery did not differ between patients and controls,
whereas skin circulation showed delayed post-occlusive hyperemia
response. They concluded that this modified kinetics of skin vaso-
dilation was presumably caused by the structural changes in
microvascular VSMCs. Experimental studies have yielded similar
results: tail arteries from transgenic mice expressing p.Arg90Cys-
mutant human NOTCH3 showed in vitro significantly decreased
flow-induced dilation (33).
In spite of the above-described systemic circulatory distur-
bances and autopsy verified structural involvement of arteries in
most organs (110), hardly any clinical manifestations other than
the neurological ones have been described. Myocardial infarctions
have been reported in a Dutch CADASIL cohort (74), but not in
some other studies, for example (14, 26, 28).
Circulatory disturbances in CARASIL
Very few studies on CBF in CARASIL have been published.
Reduced CBF has been shown with single photon emission com-
puted tomography (SPECT) and this reduction appeared to be
relatively diffusely distributed (40, 115). Since at present there is
no animal model for CARASIL, experimental studies on circula-




Macroscopic findings in CADASIL
In concordance with the imaging findings, the cerebral cortex is
relatively spared, whereas multiple small lacunar infarcts are found
predominantly in the cerebralWM and deep GM (Figure 4) as well
as occasionally also in the brain stem. The severity of the lesions
varies considerably between different, even neighboring anatomic
regions. Stenoses in large cerebral arteries and rare larger, territo-
rial infarcts (20, 85) have been reported, but they are most likely
coincidental insults, not directly related to CADASIL. Besides,
because CADASIL does not protect the patients from atheroscle-
rosis, atherosclerotic infarcts may also occur, and these often
impact also on cerebral cortex (Figure 4A).
T2*w MRI has shown that microbleeds are relatively common
in CADASIL [see Imaging in CADASIL section and figure 3A in
(113) and for pathology, Figure 10A–D] and they have been con-
sidered predictive for intracerebral hemorrhages (ICH). ICHs have
been reported to be significantly associated with microbleeds
among Chinese patients with p.Arg544Cys mutation, but on the
other hand, these patients were also hypertensive (22). However,
compared with the frequency of microbleeds, ICHs are relatively
uncommon; just over 20 cases have been reported. Thus,
microbleeds do not appear to impose a very serious threat of ICH.
It appears that the fibrotic arterioles of CADASIL are less fragile
than amyloid laden arteries in cerebral amyloid angiopathy (CAA).
A few ICHs have been purely spontaneous, but most often they
have occurred in patients, who have been hypertensive and/or
treated with anticoagulants or antiaggregants. The majority of
ICHs have been located in basal ganglia or thalamus with a few in
cerebellum (75, 107).
Histopathology post-mortem
Corresponding to MRI and macroscopic findings, the brunt of
histopathology is seen in cerebral WM and deep GM, whereas
cortical GM is involved only to a minor extent. Already in
routine hematoxylin and eosin-stained sections (Figure 5B), small
arteries in cerebral WM appear thick-walled and exceptio-
nally rounded with basophilic (Figure 5B) and PAS-positive
(Figure 5C) staining of tunica media. Fibrous connective tissue
accumulates in tunica adventitia, which may occasionally result in
complete obliteration of arterioles (Figure 5D). Immunohisto-
chemistry (IHC) discloses pathognomonic granular deposits of
N3ECD immunopositivity in tunica media (Figure 5E). In parallel,
α-smooth muscle actin (α-SMA) positivity decreases indicating
degeneration of VSMCs (Figure 5F). In tunica adventitia, various
types of collagen (Figure 5G), laminin, clusterin and other ECM
proteins accumulate. Although cerebral cortex is relatively spared,
N3ECD is also deposited in the tunica media of cortical arteries,
but the adventitial thickening is markedly more prominent in WM
arterioles (Figure 6A vs. B). Deposition of N3ECD expectedly
begins already at the presymptomatic stage (Figure 6C). At
advanced stages, N3ECD deposits are discernible also on veins
and capillaries in both cerebral WM and GM (Figure 6D and E)
and leptomeningeal arteries are also affected (Figure 6F).
The predominant pathology—thickening of vascular walls and
luminal stenosis—of arterioles, most prominent in cerebral WM
and inflicting especially arterioles of smaller caliber, was explic-
itly demonstrated by Miao et al (84). This pathology is also
clearly demonstrated in the elevation of the sclerotic index (SI)
[defined and calculated as 1 − (internal diameter/external diam-
eter)]. The SI of cerebral arterial vessels increased rapidly, when
their lumina had narrowed to 20–30 μm and external diameter
reached 130 μm. The mean SI of control persons’ arterioles was
about 0.42 in WM and 0.49 in GM, whereas in CADASIL
patients’ WM, the mean SI was 0.74 but in the relatively spared
GM it increased only to 0.55 (Miao et al unpub. obs.). Interest-
ingly, this increase in SI begins early, as in a 32-year-old
CADASIL patient’s WM arterioles the SI had reached the value
of 0.64 (85). This demonstrates the remarkable difference
between WM and GM arterioles, the pathobiological background
of which has not yet been fully clarified. This predominant
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stenosis in WM arterioles is also manifested in the reversal of the
ratio between the mean luminal size in WM vs. cortical arterioles.
In elderly controls, the mean luminal size of arterioles was found
to be larger in WM than in cortex, that is 27.0 vs. 19.3 μm and
the WM/GM ratio 1.40, whereas in elderly CADASIL patients,
the disease had rendered the lumina of WM arterioles smaller
than in cortical arterioles, that is 14.8 vs. 17.2 μm (WM/GM ratio
0.85) (Miao et al unpub. obs.).
The lacunar infarcts appear similar and follow the same
sequence of cellular changes as any small ischemic infarct inWM,
appearing at the subacute stage as a focal pannecrosis with accu-
mulation of macrophages. For considerations on pathogenetic sig-
nificance of the morphological findings, see the Pathogenetic
significance of the morphological findings section.
Biopsy findings
Electron microscopy (EM) and granular osmiophilic
material (GOM)
Baudrimont et al (7) were the first to examine a CADASIL
patient’s brain arteries by EM and they discovered granular
electron-dense extracellular material—to be later named GOM—
located in the internal part of the media, reaching the basal lamina.
No amyloid or intermediate filaments were visualized and wave-
length dispersive EM showed that this material was not specific for
mineral or metallic elements.
The deposition of GOM has proved to be an important alteration
in CADASIL. Because the arteriopathy in CADASIL is systemic,
GOM deposits can be detected in arteries of many different organs,
including dermal arterioles. GOMs are actually best preserved and
visualized in immediately fixed skin biopsies (see Biopsy findings
section; Figure 7). GOM deposits commonly have a mushroom
shape with the foot closely apposed to the VSMC plasma mem-
brane and the head projecting to the ECM. Alternatively, GOMs
are irregularly rounded bodies up to 1–2 μm in diameter, usually
located in indentations of VSMCs, the plasma membrane beneath
being decorated by pinocytotic vesicles (Figure 7B and C insets).
GOMs are also often observed in the intercellular space apparently
disconnected to VSMCs (Figure 7C). GOM itself is composed of
strongly osmiophilic (thus electron-dense) tiny granules Figure 7C
inset).
Initial immuno-EM analysis of human brain samples showed
that N3ECD accumulates at the plasma membrane of VSMCs in
Figure 5. Compared with a control person’s cerebral WM arteriole (A),
the wall of a CADASIL patient’s arteriole (B) is markedly thickened and
fibrotic, and its rigidity renders the arteriole exceptionally circular (C).
Tunica media is slightly basophilic in hematoxylin and eosin (H&E)
(B) and prominently positive in periodic acid Schiff (PAS) staining
(C). In advanced disease, the fibrosis has almost completely obliterated
the lumen (D). Similarly, as in dermal arteries, NOTCH3 extracellular
domain (N3ECD) immunopositivity accumulates in the tunica media
of the thickened WM arterioles (E). The irregularly decreased
immunoreactivity for α-smooth muscle actin (α-SMA) in the wall of a
WM arteriole reflects the degeneration of VSMCs (G). The thickened
adventitia harbors extracellular matrix proteins, here shown by collagen
type I immunohistochemistry (F). vG = van Gieson.
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close vicinity to the GOM deposits (56). Further immunogold EM
studies from our and other laboratories, using a more sensitive
methodology, revealed that N3ECD is actually a component of
GOM deposits (52, 91, 135). It is conceivable that the distribution
of N3ECD protein is heterogeneous within the GOM deposit, and
taken together the observations suggest that the concentration of
N3ECD might be highest at the foot of the GOM deposit.
Because GOM has not so far been reported in any other disease,
CADASIL is an exceptional form of dementia: it can be diagnosed
even with a simple skin biopsy. Because its arteriopathy also
involves dermal arterioles, the deposition of the above-described
GOM is a specific diagnostic feature of CADASIL. In skin biop-
sies, GOM is detectable by EM in the walls of the diseased arterial
vessels (Figure 7) as well as inconsistently of veins and rarely of
capillaries. GOM appears to be present in all CADASIL patients
with a pathogenic NOTCH3 mutation that causes an uneven
number of cysteines in the affected EGFr of N3ECD (122) (for
details see Diagnosis of CADASIL and CARASIL section). Thus,
electron microscopists consider EM analysis a highly reliable
diagnostic method (92, 122). The article by Tikka et al (122)
presents a practical approach to the EM diagnostics of CADASIL,
including directions for the light microscopic selection of repre-
sentative small dermal arteries for EM thin sectioning as well as
interpretation of EM findings to discriminate between fallacious
and true GOM deposits.
IHC of N3ECD
However, because the number of laboratories available for per-
forming reliable EM examinations is limited, immunohistochemi-
cal demonstration of N3ECD in skin biopsy was proffered as an
alternative (Figure 8) (58). It is highly sensitive (85%–95%) and
specific (95%–100%), although the inherent caveats of IHC must
be kept in mind. Furthermore, its applicability at an early stage of
CADASIL with minimal amount of N3ECD/GOM remains to be
clarified (Figure 7B). With EM, we (HK) have detected GOM in a
p.Arg133Cys patient already at the age of 19 years (Figure 7B
inset), and positive IHC diagnosis (AJ) was also obtained already
in a 28-year-old young adult patient (58). In confocal microscopy,
N3ECD immunopositivity appears as delicate dots on VSMCs
(Figure 8B), in concordance with the scattered appearance of
GOM deposits in EM.
As mentioned earlier a great majority of patients with unpaired
cysteine in an EGFr of N3ECD appear to harbor GOM/N3ECD
Figure 6. The lumina of a WM (A) and a cortical (B) arteriole are
approximately as wide and approximately similar amount of N3ECD is
deposited in their tunica media, but the wall of the WM arteriole is
almost fourfold thicker than that of the cortical arteriole because of
the marked fibrosis. N3ECD is also deposited in the wall of a probable
vein beside the arteriole (B). Delicate N3ECD immunopositivity is
already present in the wall of a markedly thickened arteriole in the
cerebral WM of an only 32-year-old male CADASIL patient (C). In an
elderly patient, N3ECD immunopositivity is seen on capillaries in both
cerebral WM (D) and cortex (E), as well as in the walls of larger
leptomeningeal arteries (F).
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deposits and therefore the presence of such a cysteine residue
has been suggested to be causally associated with the formation
of GOMs. However, non-cysteine mutations have been discovered
in several patients with a SVD compatible with the CADASIL.
Interestingly, in EM unequivocal, GOM has been reported
only in two Japanese families with a non-cysteine mutation
(p.Arg75Pro), in whom despite extensive search cysteine involv-
ing Notch3 mutation was not detected (87). We have not detected
GOM in any of the seven non-cysteine cases that we have exam-
ined (Kalimo, unpub. obs.).
In addition to GOM deposits, EM also shows several
degenerative alterations in the small arterioles: widening of
subendothelial spaces, fragmentation of inner elastic lamina
and presence of degenerating VSMCs with accumulation of cell
debris in the extracellular space around them (122) (Figure 7A
and C).
PATHOLOGY OF CARASIL
The main cerebrovascular pathology in CARASIL falls on the
same vascular bed as CADASIL, that is the small penetrating
arteries, mainly in the cerebral WM and basal ganglia (6, 39).
Histopathologically, the arteries show advanced arteriosclerosis
(Figure 9B and C) without the light microscopic basophilic granu-
larity of tunica media or electron microscopic GOM onVSMCs as
















Figure 7. An electron micrograph (EM) of a small dermal artery from a 28-year-old male CADASIL patient with p.Arg133Cys NOTCH3 mutation. Three
small deposits of GOM (arrows) are detectable (already at this age) on a few vascular smooth muscle cells (VSMC). The subendothelial space is
widened with accumulation of extracellular matrix proteins (asterisks). E = endothelium, N = nucleus (A). An EM of a dermal arteriole from a
19-year-old CADASIL patient [younger brother of the patient in (A), both sons of a male patient homozygous for p.Arg133Cys mutation] shows the
paucity of GOMs (arrowhead) and the inset shows that true GOMs do occur already at this young age (B). A higher magnification EM of a dermal
arteriole from an elderly patient at a more advanced stage of the disease. GOMs are present both in indentations on a VSMC (black asterisks) and
in the intercellular space apparently disconnected to the VSMC (white asterisk) (C). Note the pinocytotic vesicles in the VSMC beneath the GOM (B
and C insets). N = nucleus. [Fig. 7A is reproduced from article (62) with permission]
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fibrous thickening, internal elastic lamina is fragmented and media
reveals loss of VSMCs with subsequent hyalinization. Arterial
lumina are concentrically narrowed, but occasionally segmental
dilation occurs. These vascular pathologies result in multifocal
ischemic infarcts as well as diffuse ischemic changes, especially in
cerebral WM (diffuse myelin loss with preservation of U-fibers;
Figure 9A) and consequent moderate atrophy. As there is no char-
acteristic alteration in the diseased arteries, such as GOM in
CADASIL, skin biopsies do not provide any diagnostic help,
neither is the systemic nature of CARASIL similarly evident as it
is in CADASIL. The vascular changes in other organs affected are
less severe than those in cerebral arteries.
DIAGNOSIS OF CADASIL AND CARASIL
The diagnosis of the patients, whose clinical picture is suggestive
of CADASIL should be confirmed, both to inform the patient and
to give correct counseling to the family members. Genetic testing
is naturally the gold standard for the diagnosis of CADASIL. With
the already wide knowledge of CADASIL, many genetic labora-
tories can provide even the full screening of the 21 (2–15, 18–24)
exons that harbor the pathogenic NOTCH3 mutations. The speci-
ficity of mutations that lead to an uneven number of cysteines
within any of the 34 EGFrs in N3ECD is 100% and the sensitivity
of the analysis is close to 100% (14). However, in selected cases,
Figure 8. Immunohistochemical visualization of N3ECD deposition in the walls of dermal arteries (asterisks). The granular immunoreactivity is
visualized either by using immunoperoxidase method (A) or—at a higher resolution—using confocal immunofluorescence, the punctate pattern being
consistent with scattered distribution of GOMs (B). N = nerve.
Figure 9. The cerebral white matter of a
CARASIL patient who died at the age of 54
years shows diffuse widespread loss of
myelin with preservation of U-fibers (A).
A small artery from a cerebral white matter
shows irregular structure with double
barreling of the thickened wall. Internal
elastic lamina is multiplied (B). The wall of
a medium-sized leptomeningeal artery is
markedly thickened with replacement of
tunica muscularis by fibrous tissue, intimal
proliferation and splitting of the internal elastic
lamina. The smaller arteries beside show
loose double barreling (C).
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neuropathology can be used to ascertain the diagnosis: (i) if reli-
able genetic screening is not readily available or (ii) if genetic
screening gives an equivocal (especially non-cysteine mutations),
negative or previously unknown result (see Pathology of
CADASIL section).
The clinical picture of premature alopecia, low back pain in
addition to the neurological symptoms and presence of diffuse
WM lesions in MRI should alert the clinician, especially in Far
Eastern countries, to consider CARASIL as a possible, although a
rare alternative. Similar patients among relatives indicating a
hereditary disease is, of course, an important lead. The rarity of
CARASIL in outside of Asia, of course, further increases the
challenge in those countries. Thus, prompt molecular genetic
analysis is warranted and demonstration of a pathogenic mutation
in HTRA1 gives the definite diagnosis. As mentioned earlier,
skin biopsy is not an auxiliary method, although it is helpful in
differential diagnosis between CARASIL and CADASIL. The
differential diagnostic alternatives for CARASIL have been pre-




Although the defective gene NOTCH3 that causes CADASIL has
been identified almost 20 years ago and skilled research teams
have striven to explain disease pathogenesis, the final goal has not
yet been reached. The basic question whether the disease is caused
by the loss-of-function or gain-of-function appears to become
settled in favor of the latter alternative (see Neomorphic and toxic
gain of function section).
Pathogenetic significance of the
morphological findings
Vascular alterations
Stenosis of the affected arteries has been unequivocally demon-
strated, but the decisive pathology—occlusion or thrombosis—of
the feeding artery that leads to the lacunar infarct is rarely identi-
fied, although occasional completely obliterated arterioles may
be detected (Figure 5D). In WM, where arteriolar stenosis is
unequivocal, occlusion and/or thrombosis are most likely the pre-
dominant cause of the ischemic lesions. However, the arterioles
with thickened and fibrotic walls, even if they are not significantly
stenosed, do also bring on a risk of infarction, as demonstrated in
deep GM (basal ganglia), where lacunar infarcts are common.
Such arterioles have evidently lost their compliance and
autoregulation, and thus the lacunar infarcts may also be caused
by hemodynamic disturbances to which the rigid arterioles are
not able to respond by dilatation, and critical ischemia occurs,
although significant stenosis as such does not prevail (86, 119). On
the other hand, experimental studies on transgenic mice expres-
sing rat p.R169C mutant Notch3 (a preclinical mouse model
of CADASIL) have shown cerebrovascular dysfunction with
impaired neurovascular coupling and autoregulation of cerebral
blood flow already prior to the appearance of fibrosis [and stenosis
(60)]. Thus, the problem may be also functional and not only
mechanistic.
In CADASIL, the blood–brain barrier (BBB) is often multi-
focally breached as indicated by the common appearance of mul-
tiple microbleeds in T2*wMRI [see Imaging in CADASIL section
and figure 3A in (113)]. Rarely, small fresh cortical hemorrhages
may be detected already during brain cutting (Figure 10A).
Histopathologically, microbleeds appear as small perivascular
hemosiderin or immunopositive plasma protein deposits around
cortical/GM arterioles (Figure 10B and C), the walls of which are
markedly thinner than in WM arterioles (Figure 10D vs. E), a
likely reason for the predominant location of microbleeds in GM
regions. IHC for plasma proteins shows that BBB is breached only
locally at the sites of microbleeds or infarcts (Figure 10C–G),
whereas the damage of the vascular walls does not appear to cause
a more generalized breakdown of BBB that would result in wide-
spread extravasation of plasma proteins and consequent vasogenic
edema (Figure 10E–G). This suggests that the increased amount of
free extracellular fluid detectable with DTI appears because of a
CADASIL-specific type of vasogenic edema.
Tissue alterations
The interpretation of the DTI findings earlier agrees well with the
analysis of the microstructural changes in transgenic mice express-
ing rat wt or p.Arg169Cys-mutant Notch3 (25, 60). These mice are
considered an animal model, in which the vascular and WM
pathologies correspond to human preclinical CADASIL. It was
demonstrated that in cerebral WM, myelin damage occurs first
without loss of oligodendrocytes or major damage of axons
(Figure 11). The axonal injury appears to be secondary to myelin
degradation. These findings agree with the lack of an overt phe-
notype in these mice as well as with the fact that prominent MRI
changes may be seen already in presymptomatic CADASIL
patients’ WM. The early WM lesions in these mice and hence in
CADASIL were ascribed (linked?) to hypoperfusion-induced
energy deficiency, which causes failure of ATP-dependent ion
pumps and consequent impaired ion and water homeostasis. This
leads to intramyelinic edema (Figure 11) (25), which in previous
experimental studies has been shown to be a very early pathologi-
cal change in ischemic WM (99). Chronic hypoperfusion in
WM has been demonstrated both in the transgenic mouse model
earlier (60) and in young CADASIL patients (127). Alternatively,
impaired ion and water homeostasis could arise from a dysfunction
of the astrocytic endfeet which cover the abluminal surface of
pericytes and smooth muscle cells, where mutant Notch3 accumu-
lates aberrantly (25).
Processing and trafficking of mutated Notch3
The full-length Notch3 is constitutively cleaved (site 1 = S1
cleavage) in the Golgi apparatus by furin (79) and targeted to the
cell surface to form the heterodimer (N3ECD + N3TMIC, see
Genetics and Biochemistry: CADASIL section and Figure 1)
transmembrane receptor. It has been suggested that abnormal pro-
cessing and trafficking of mutated Notch3 could be the cause of
CADASIL. As almost all pathogenic mutations lead to an uneven
number of cysteine residues in the mutated EGFr, the normal
formation of sulphur bridges is prevented and thus misfolding of
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Notch3 most likely occurs. However, misfolded Notch3 proteins
appear to escape the normal cellular quality control, ubiquitylation
and proteosomal degradation, and are correctly processed and
transported to cell surface in their partially misfolded state.
For example, in genuine patient-derived VSMCs (with p.R133C
mutation) cultured in vitro, the S1 cleavage appeared to occur
correctly and intracellular aggregates were not more frequent than
in control VSMCs. This suggests that in human VSMCs the
microenvironment in Golgi and ER is able to prevent intracellular
interreceptor cross-linking and aggregation of the mutated endog-
enous Notch3 (123). Thus, the characteristic aggregation of
N3ECD does not appear to occur until the receptor has reached the
cell surface and therefore the accumulation of N3ECD on VSMCs
is most likely because of its local aggregation and/or its impaired
clearance (34, 91).
In experimental studies, normal intracellular processing, traf-
ficking and signaling were reported by Joutel et al (59) in cells
transfected with human NOTCH3 harboring three different muta-
tions and by Low et al (80) with NOTCH3 harboring four different
mutations. However, in a study by Peters et al (100), cells
transfected with mutated human NOTCH3 (p.R133C, p.C183R
and p.C455R) showed reduced S1 (furin) cleavage. In another
study, in cells transfected with mutated mouse mNotch3, a lesser
amount of the overexpressed mutated than wt mNotch3 was trans-
ported to the cell surface. Besides, intracellular aggregates were
formed, which may have resulted from increased accumulation or
slowed transport in the secretory pathway (63). Abnormal S1
cleavage was also reported in cells expressing mutated rat Notch3,
but presentation of this Notch3 on the cell surface was preserved
(46). Yet, in the latter three studies, signaling by these mutated
Notch3 receptors was not compromised. Thus, defective
proteolytic processing or intracellular trafficking does not appear
to be the key problem in CADASIL.
Impaired Notch3 signaling
Although many of the studies earlier have shown that mutated
Notch3 retains its canonical signaling, loss of function has not
Figure 10. Occasionally microbleeds (arrows) in cerebral cortex
may be visible already during brain cutting (A). An accumulation of
hemosiderin around a cortical arteriole stains strongly positively for iron
(B). The breached BBB at the microbleed leaks plasma fibrinogen
(brown; C). The wall of a cortical arteriole (D) is markedly thinner than
that of a WM arteriole (E; blue bars in D vs. E), while their outer
diameters (red bars) are of approximately the same magnitude. This is
a likely explanation for the predominant location of microbleeds in
cortical and deep GM. The thick wall of a WM arteriole from a CADASIL
patient at a quiescent stage of the disease has not allowed virtually any
leakage of fibrinogen (E). Extravasated fibrinogen is normally taken up
by Purkinje cells (PCs) from cerebrospinal fluid (51). Thus, negative
fibrinogen staining of cerebellar PCs (arrows; F) verifies that significant
leakage has not occurred in this patient at a quiescent stage, whereas
in another CADASIL patient, who had suffered an infarct just before
death, PCs (arrows) are strongly immunopositive for fibrinogen reflect-
ing the breakdown of BBB (G).
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been fully abandoned as a possible pathogenetic mechanism.
Hypomorphic Notch3 function was suggested by Arboleda-
Velasquez et al (5) to be associated with CADASIL pathophysiol-
ogy. They applied an in vivo assay, with which they showed that
mutated (p.Cys455Arg or p.Arg1031Cys) NOTCH3 transgenes
did not rescue the ischemic susceptibility phenotype of Notch3
knockout mice (evaluated by measuring the infarct size after stand-
ard filament occlusion of middle cerebral artery) as efficiently as
wt NOTCH3. They also demonstrated decreased signaling activity
in embryonic fibroblasts from transgenic mice expressing the
above-mentioned mutated NOTCH3 genes co-cultured with ligand
Delta-like 1 expressing cells.
However, in some patients, CADASIL is caused by mutations at
the ligand binding site, which abrogate ligand binding to Notch3
(Figure 1). Yet, the clinical pictures of these patients and of those
with mutations outside the binding site are very similar. Thus, it is
somewhat difficult to accept that the loss of function would be the
sole/main cause of CADASIL. This view is supported for example
by the experiments of Joutel et al (59) and Peters et al (100), who
demonstrated in vitro that only Notch3 with specific muta-
tions located in the ligand binding site in EGF repeats 10–11
(p.Cys428Ser and p.Cys455Arg) exhibited significantly reduced
transcriptional activity via the RBP-Jκ pathway, whereas the tested
Notch3 receptors with mutations located outside the binding site
had nearly normal signaling activity. In another set of in vivo
experiments, the physiological levels of both wt human NOTCH3
and mutant p.Arg90Cys human NOTCH3 rescued the arterial
defects of Notch3 knockout mice to similar degrees and mutant
Notch3 exhibited normal level of Notch3/RBP-Jκ activity in brain
arteries (89). Furthermore, Notch3-deficient (knockout) mice do
not develop CADASIL pathognomonic GOM deposits or
CADASIL pathology (23, 24, 65, 67), whereas they do appear in
transgenic mice expressing mutant Notch3 (5, 89, 111), but these
deposits do not interfere with Notch3/RBP-Jκ signaling activity
(23, 24, 89). Finally, elimination of wt Notch3 did not influence the
onset and burden of WM lesions in the TgPAC-Notch3R169C mice
(23). Besides, the similar phenotype in the homozygous and
heterozygous CADASIL patients (126) as well as the lack of
truncating mutations in CADASIL (100) also favor a mechanism
other than loss of the canonical Notch3 function.
Neomorphic and toxic gain of function
Thus, majority of CADASIL studies seem to favor a neomorphic
(gain of novel function) pathogenetic mechanism rather than com-
promised canonical Notch3 function. The alteration that is
common to all CADASIL mutations is the accumulation of
N3ECD on the VSMC surface; unpaired cysteine residue with
consequent partial misfolding and/or abnormal glycosylation of
Notch3 seem to cause aberrant dimerization and higher order
multimerization with cross-linking by disulphide bonds, which
results in the aggregation and deposition of N3ECD on VSMC
surface (5, 34, 91). This aggregation phenomenon was also dem-
onstrated in several transgenic mice expressing mutated
(p.Arg90Cys or p.Cys428Ser) human Notch3 or (p.Arg169Cys) rat
Notch3 and in a knocked-in mouse model expressing the corre-
sponding mouse p.Arg169Cys mutation, which did accumulate
N3ECD on VSMCs like in CADASIL patients (23, 24, 89, 90,
111). Normally, N3ECD is transendocytosed into the ligand-
expressing cell and degraded through the endocytic-lysosomal deg-
radation pathway (44). The observation of abnormal accumulation
of N3ECD in the vascular wall without accumulation of N3TMIC
has raised the possibility that upon ligand binding, mutant Notch3
might be refractory to transendocytosis and further degradation
(134). However, against this possibility speaks the observation that
both transgenic mice and patients carrying the p.Cys428Ser muta-
tion, which abolishes binding of the DSL ligands to Notch3, harbor
vascular N3ECD deposits (59, 90). How mutated N3ECD may
cause degeneration ofVSMCs and the other con/subsequent patho-
genic alterations has remained enigmatic.
Most studies have shown that neither most mutations in Notch3
nor accumulation of N3ECD compromise the canonical signaling,
yet this accumulation appears to be pathogenic. The retention of
misfolded N3ECD with an unpaired cysteine, could result in novel
protein–protein interactions and induce (inactivate or aggravate)
Figure 11. (A) Representative electron micrographs of the corpus
callosum from a TgPAC-Notch3R169C showing multiple membrane-bound
vacuoles (colored in pink) including numerous inframicrometric vacuoles
(white arrows). O = oligodendrocytes (colored in green); A = astrocyte
(colored in purple); C = capillary (colored in yellow). (B) Typical large
vacuole (asterisk) in the innermost layer of the myelin sheath. The
vacuole separates the axon from its myelin sheath (black arrowheads)
and contains multiple aberrant myelin sheets (arrows). Notice the thin
myelin sheet (open arrowhead) at the interface between the axon and
the vacuole. Scale bar represents 5 μm in (A) and 1 μm in (B).
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still unknown functions/dysfunctions that are toxic to VSMCs. A
recent study showed that N3ECD deposits can make up a platform
or act as a seed that promotes interactions with ECM proteins, such
as tissue inhibitor of metalloproteinases 3 (TIMP3), that in turn
can bind and recruit more and more proteins, such as vitronectin,
generating new interaction surfaces and magnifying the toxic
potential of aggregates in a snowball effect (91).Abnormal seques-
tration of proteins into aggregates usually results in the collapse of
their biological function (98). TIMP3 and vitronectin have multi-
ple biological activities that are directly relevant to CADASIL
pathogenesis. For example, TIMP3 dysregulation could contribute
to small vessel pathology through its well-known metallo-
proteinase inhibitory activity. Also, by its ability to bind and
stabilize plasminogen activator inhibitor-1, vitronectin could
modulate the balance of the fibrinolytic system, and consequently,
the ECM homeostasis. Further studies are required to examine
whether and how focal TIMP3 and vitronectin deposition can alter
their biological activities and contribute to the disease process.
Intriguingly, our preliminary studies showed an unexpected eleva-
tion of TIMP3 activity in the brain vessels of both CADASIL
mouse models and patients with CADASIL.
A definite response is the degeneration of VSMCs with conse-
quent impairment of vasomotor functions. This is reflected in the
pathology of the key smooth muscle cell contractile protein
α-actin (interestingly, α-actin is a direct target of canonical Notch3
signaling, yet disturbance in this pathway was by and large
excluded). In cultured genuine human CADASIL (p.Arg133Cys)
VSMCs, several proteins interacting with actin cytoskeleton were
differentially expressed and the contractile capability of these
VSMCs was impaired (50). In these cells, the actin cytoskeleton
showed many derangements, the severity of which varied in
VSMCs from different vascular beds being most severe in VSMCs
derived from adult cerebral arteries. Again in slight disagreement
with the above-described lesser pathogenicity of hypomorphic
Notch signaling, short hairpin RNA (shRNA) silencing of
NOTCH3 in control cells did cause similar derangements of actin
as in the p.Arg133Cys mutant humanVSMCs (123). Furthermore,
these cells disclosed also other features of hypomorphic Notch3
signaling by showing reduced upregulation of expression of
Notch3 target genes PDGFR-β, HES1 and HEY1 in response to
ligand activation (53).
Degeneration of VSMCs is followed by increased production of
ECM proteins resulting in marked thickening of the arterial walls,
stenosis and decreased compliance [see above Pathology of
CADASIL section and (84)]. Whether this is a general response to
degeneration of VSMCs or because of the activation of Notch-
specific fibrotic pathways is still to be examined (see discussion on
TGF-β signaling in CARASIL). By IHC, it has been shown that in
CADASIL types I, II, IV and VI collagens are consistently
increased in the walls of all caliber arterial vessels (31). These
findings agree well with those in the study by Monet-Leprêtre et al
(91) in which the activity of TIMP3 was significantly elevated in
both human patients and transgenic mouse model of CADASIL, as
such an anticipated finding in vessel fibrosis reflecting reduced
degradation of ECM components. Whether fibrosis also reflects
transformation of VSMCs from contractile to productive mode
like in atherosclerosis (68) is not known, although becauseVSMCs
are degenerating, the most likely cell to produce ECM proteins is
fibroblast.
CARASIL
Contrary to the complicated pathogenesis in CADASIL, the patho-
genetic mechanisms in CARASIL appear relatively straightfor-
ward (45, 97, 116). As described in more detail in the section
Genetics and Biochemistry, the function of HTRA1 as a repressor
of TGF-β signaling by cleaving proTGF-β1 in the ER results in
reduced amounts of mature TGF-β1 in the ECM. HTRA1 muta-
tions have been demonstrated to result in its decreased function
and consequently in greater amounts of mature TGF-β and
upregulation of TGF-β signaling. TGF-β plays a critical role in
ECM accumulation and vascular remodeling via upregulating the
production of several agents including connective tissue growth
factor (CTGF) and fibroblast growth factor. It has been shown to
be the key mediator of vascular fibrosis (71). Concordantly, with
the skeletal pathologies in CARASIL, TGF-β also uniquely coor-
dinates bone cell activity to maintain bone homeostasis. It regu-
lates the differentiation and function of both osteoblasts and
osteoclasts, from lineage recruitment to terminal differentiation,
thereby balancing bone formation and resorption (121).
THERAPEUTIC ASPECTS
CADASIL
Because CADASIL is an autosomal dominant genetic disease,
preventing the expression of the mutated pathogenic allele of
NOTCH3 should—if successful—provide definite therapy. Based
on the assumption that the decisive pathogenesis is the toxic gain
of function, probably associated with the unpaired cysteine in the
affected EGFr/EGFrs, there are two possible gene therapeutic
approaches: (i) silencing the mutated gene allele with inhibitory
RNA molecules and (ii) antisense-mediated skipping of the
NOTCH3 exon harboring the defective DNA sequence. Allele-
specific siRNAs have already been designed for several diseases,
including familial forms of Alzheimer’s disease, Parkinson’s
disease, amyotrophic lateral sclerosis and spinocerebellar ataxia 7
(66, 114). Tikka et al (123) demonstrated efficient silencing of
NOTCH3 in control VSMCs (from human umbilical artery)
transfected with two different vectors (by 36% respectively 63%),
which encode shRNAs targeting NOTCH3 gene. This predicts that
the expression of the mutated NOTCH3 could also be silenced and
thereby the assumed toxic effect could be prevented. Because of
the great number of pathogenic mutations this approach would
require a production of very many vectors to specifically silence
only the pathogenic allele. A more inclusive possibility would be
antisense-mediated exon skipping, which is emerging as a prom-
ising gene therapy to combat Duchenne muscular dystrophy, a
hereditary disease with a markedly larger number of different
mutations than in CADASIL (1, 49). This approach would be
advantageous also in CADASIL, because skipping of a few exons,
for example exons 3 and 4 encoding EGFr 2–5, which harbor a
large cluster of missense mutations [>40% of mutations in >70%
of families occur in these exons (18)], could—if successful—
produce a truncated Notch3 in which the unpaired cysteine is
eliminated, but at the same time it should still remain capable of
implementing Notch3 functions. Thus, a limited number of skip-
ping procedures could help many patients. The location of VSMCs
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just beyond the endothelium from circulating blood may well
facilitate delivery of the antisense oligonucleotides to the target
cell, VSMC.
Despite the promising gene therapeutic views, at present, only
symptomatic therapy is available, beginning with the simple rec-
ommendation to refrain from smoking. If the migraneous head-
ache requires medication, conventional “pain killers” are
recommended, whereas treatment with classic migraine drugs,
such as ergotamines or triptans is discouraged because of their
vasoconstrictory effect (13). Exceptionally, acetazolamide has
been applied to alleviate acute excruciating migraine attacks (36).
Anticoagulants and antiaggregants have been tried without defi-
nite positive effects; rather these medications may have caused a
few fatal parenchymal brain hemorrhages. As the progressive
stenosis and rigidity already impair blood flow in the diseased
arterioles, increased blood viscosity, for example because of
polycythemia or dehydration, appears to be harmful and should be
avoided (Viitanen, unpub. obs.). On the same basis, medications
which cause cerebral hypoperfusion, such as antihypertensive
drugs, tricyclic antidepressants and neuroleptics, should be admin-
istered with caution. Because one-half of the CADASIL patients
have hypercholesterolemia, treatment with statins is indicated,
although the role of statins in CADASIL per se is still unknown
(102).
Cognitive decline begins already before ischemic attacks.
Cholinergic deficits have been found in CADASIL patients in late
middle age (64) and therefore cholinesterase inhibitors may alle-
viate cognitive decline. In a placebo controlled study with
donepezil, executive functions were improved moderately but the
clinical relevance of this treatment is still unknown (30).
CARASIL
For CARASIL, there is at present no effective treatment (39).
The genetic defect causes a loss-of-function of HTRA1, which
would necessitate inducing production of functional HTRA1 (or
administration of another molecule capable of repressing TGF-β
signaling). Thus, similar approaches as suggested earlier for
CADASIL, in which the toxic gain-of-function now seems to be
the plausible pathogenic mechanism, are not possible. Shiga et al
(116) and Nozaki et al. (97) proposed interesting approaches to
treat patients carrying a nonsense mutation of HTRA1.
Preventing/alleviating the nonsense-mediated decay of mutated
mRNA might be effective in increasing truncated p.Arg370X
HTRA1, which has been shown to retain normal protease activ-
ity, since the truncated C-terminal PDZ domain of HTRA1 was
revealed to be dispensable (18, 97, 117). Alternatively a drug
(e.g. aminoglycoside antibiotics) that suppresses the identifica-
tion of the translation termination codon (induced by the muta-
tion), may allow, sufficient production of active HTRA1 and thus
repression of TGF-β signaling could be rescued.
The treatment at present includes prevention of non-CARASIL-
related ischemic stroke, genetic counseling, supportive care and
medications for treating dementia. The roles of antithrombotic and
anticoagulant drugs in the therapeutics are still unclear (39).
Because excessive TGF-β signaling appears to be the major
culprit in CARASIL, another approach—direct inhibition of
TGF-β signaling—has been suggested to be investigated as a
therapeutic strategy (97). This suggestion is based on the fact that
in Marfan syndrome, which is also caused by increased TGF-β
signaling, angiotensin I receptor antagonist (a drug in clinical use
as antihypertensive) has been shown to inhibit TGF-β signaling
and ameliorate the progression of Marfan syndrome in both trans-
genic mice and patients. In human brain, angiotensin I receptor
antagonist also inhibits TGF-β signaling (97).
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